酪氨酸激酶抑制剂凡德他尼所致药物相关性肠病一例
金梦;郭涛;李景南;
摘要(Abstract)：
<正>药物相关性肠病在临床上相对少见,临床医生对其认识不足,往往易被漏诊。本文报道1例因腹痛、腹泻、便血待查就诊而最终确诊为酪氨酸激酶抑制剂凡德他尼所致药物相关性肠病患者。临床资料患者男,40岁,因"反复腹痛、腹泻2年余,间断便血1年余"于2014年9月12日入住本院。患者2012年3月因甲状腺髓样癌服用酪氨酸激酶抑制剂凡德他尼(vandertanib,又名凡他尼布),300 mg每天1次,此后反复发作下腹阵发性绞痛,伴腹泻
关键词(KeyWords)：
凡德他尼;酪氨酸激酶抑制剂;药物相关性肠病
基金项目(Foundation):
作者(Authors):
金梦;郭涛;李景南;
参考文献(References)：
- [1]庞若,金波.凡德他尼在非小细胞肺癌治疗中的进展[J].中华临床医师杂志,2012,6:8264-8267.
- [2]Wells SA Jr,Robinson BG,Gagel RF,et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized,double-blind phase III trial[J].J Clin Oncol,2012,30:134-141.
- [3]Drappatz J,Norden AD,Wong ET,et al.Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma[J].Int J Radiat Oncol Biol Phys,2010,78:85-90.
- [4]Hapani S,Chu D,Wu S.Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:a meta-analysis[J].Lancet Oncol,2009,10:559-568.
- [5]Qi WX,Sun YJ,Tang LN.Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors:a systematic review and meta-analysis[J].Crit Rev Oncol Hematol,2014,89:394-403.
- [6]Kamba T,Tam BY,Hashizume H,et al.VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature[J].Am J Physiol Heart Circ Physiol,2006,290:H560-H576.